Favourable West Nile vaccine results
Friday, 27 February, 2009
Early results from a Phase I safety and efficacy trial of a West Nile virus vaccine, being developed by Acuvax’s US affiliate Hawaii Biotech, are “stunning”, the company said.
The results will enable an easier roll-out for a dengue fever vaccine, Acuvax’s CEO Dr William Ardrey said in a statement.
Hawaii Biotech, a private company in which Acuvax has a substantial shareholding, is trialling its vaccine in 24 healthy volunteers to check safety and antibody development.
All volunteers showed the presence of neutralizing antibodies. The vaccine is based on a proprietary recombinant DNA technology platform, which is being used by Hawaii to develop a vaccine for dengue fever, as well as candidates for malaria, tick-borne encephalitis virus and flu.
The company will now begin trials in children, the elderly and immuno-compromised patients.
TGA approves first treatment for geographic atrophy
Australia has become the first country outside of the United States to approve the use of the...
Damaged RNA, not DNA, revealed as main cause of acute sunburn
Sunburn has traditionally been attributed to UV-induced DNA damage, but it turns out that this is...
Multi-ethnic studies identify new genes for depression
Two international studies have revealed hundreds of previously unknown genetic links to...
